Background and objectives Disease-specific treatment options for autosomal dominant polycystic kidney disease are limited. Clinical intervention early in life is likely to have the greatest effect. In a 3-year randomized doubleblind placebo-controlled phase 3 clinical trial, the authors recently showed that pravastatin decreased heightcorrected total kidney volume (HtTKV) progression of structural kidney disease over a 3-year period. However, the underlying mechanisms have not been elucidated.
Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease, occurring in one in 400 to one in 1000 live births (1) . Approximately one half of affected patients develop ESRD by age 60 years. ADPKD is characterized by progressive cyst development and enlarged kidneys with multiple cysts. ADPKD is a genetic disease, and interventions provided early in life should have the highest success to inhibit its progression.
Our previous observational studies showed that children with ADPKD and hypertension have larger kidney volumes compared with their counterparts with normotension (2, 3) . There is a significant association between left ventricular mass index (LVMI) and renal volume in children with hypertension (4) . We previously showed that angiotensin-converting enzyme inhibitors (ACEIs) reduced the decline of creatinine clearance and the increase in LVMI in pediatric ADPKD, but they did not affect progression of structural kidney disease (5) .
Statins were shown to reduce the severity of PKD in heterozygous Han:Sprague-Dawley cystic rats (6, 7) and to improve renal function in short-term studies in adults with ADPKD (8) . Although the underlying mechanisms are not well understood, it has been proposed that these renoprotective effects are mediated by statin-related inhibition of G proteins, resulting in decreased cell proliferation (6) .
On the basis of these findings, we designed a 3-year randomized double-blind placebo-controlled phase 3 clinical trial to determine the effect of pravastatin on kidney and cardiovascular disease progression in children and young adults with ADPKD who were receiving the ACEI lisinopril (9) . The positive outcome of the study (10) supports early therapeutic intervention and pravastatin as an effective agent to slow the progression of ADPKD. However, the underlying mechanisms of this beneficial effect remain to be defined.
We and others have shown that adult patients with ADPKD have elevated levels of cardiovascular disease risk and oxidative stress markers compared with healthy individuals (11) (12) (13) (14) (15) (Figure 1 ). These as well as inflammatory bioactive lipid mediators were elevated early in the disease and were associated with the increase in total kidney volume (TKV) and decline in renal function (14, 16, 17) (Figure 1) .
On the basis of this knowledge, we aimed to investigate whether the markers of endothelial dysfunction, inflammation, and oxidative stress identified in previous studies (11, (13) (14) (15) (16) (Figure 1 ) change in response to pravastatin therapy. This would qualify their use for monitoring of ADPKD disease progression and therapy efficacy. Plasma and urine samples from the above-mentioned clinical trial were used and biomarkers were correlated with changes in height-corrected total kidney volume (HtTKV).
Materials and Methods

Trial Design
For this study, we used plasma and urine samples collected during the referenced clinical trial (9, 10) . Eligible participants were aged 8-22 years and had ADPKD with a Schwartz eGFR.80 ml/min per 1.73 m 2 (18) .
Each participant was evaluated during a 2-day admission at the Clinical Translational Research Center at Children's Hospital Colorado in Aurora, Colorado. Participants provided a detailed history and underwent a physical examination including growth parameters and Tanner staging (19) (20) (21) . On the first night of admission, participants fasted for a 10-hour period and then blood was drawn for various analyses, including the biomarkers. Within 2 hours of collection, EDTA plasma tubes were frozen and stored at 270°C until analysis. Two 24-hour urine collections were obtained for creatinine, microalbumin, and eGFR determination (18) . For biomarker analysis, urine from the second collection was used. Urine was stored at 4°C during the 24-hour collection; afterward, aliquots were made, frozen, and stored at 270°C until analysis. An additional centrifugation step (for 10 minutes at 400g) occurred before the liquid chromatography-mass spectrometry analysis. Twelve sitting BP measurements were obtained in the right arm (Dinamap Pro 300V2; GE Medical Systems Information Technology, Tampa, FL) and were related to published data for age-, sex-, and heightmatched children (22) . At the conclusion of the baseline visit, research participants were randomized to receive pravastatin or placebo for the remainder of the 3-year study. The standard dosage of pravastatin was based on age as follows: 20 mg daily (8-12 years) or 40 mg daily (13-22 years). All participants were treated with the ACEI lisinopril (10) . At 18 and 36 months after the initial visit, participants returned for repeated admission, during which time they underwent the same study procedures described above (10) .
The study protocol was approved and routinely reviewed by the Colorado Multiple Institutional Review Board. This clinical trial was registered at ClinicalTrials.gov (identifier NCT00456365). The study was in full compliance with the principles of the Declaration of Helsinki and its amendments. All patients and/or guardians gave written informed assent or consent as applicable.
Concentrations of biomarkers in healthy individuals were obtained from the literature (as referenced). Because of the unavailability of normal ranges for urinary hydroxyeicosatetraenoic acid (HETE) compounds, we determined them in house in the spot urine of 15 healthy adult volunteers (10 men and five women, also normalized to creatinine).
Analyses of Abdominal Magnetic Resonance Imaging
DICOM images were deidentified and TKV was measured by stereology (23,24) (Analyze 9.0; Mayo Foundation, Biomedical Imaging Resource Core, Rochester, MN) by a single analyst who had no knowledge of the patient's status. To account for normal growth in children, TKV was corrected for height.
Since ACEIs prevented the decrease in creatinine clearance and the increase in LVMI, but they did not affect kidney volume growth (5), change in HtTKV was chosen as the primary correlation parameter. Furthermore, HtTKV serves as a better predictor than baseline age, serum creatinine, BUN, urinary albumin, or monocyte chemotactic protein-1 excretion for the onset of renal insufficiency (25, 26) . (11, 16, 44) . A vicious cycle is created in which renal cysts activate the RAAS, and the resulting increase in AngII leads to (1) increased levels of eNOS inhibitor ADMA, which further depletes NO; (2) increased HCy and SAH levels within the methylation pathway and diminished methylation capacity (SAM/SAH); and (3) increased metabolism of AA, leading to generation of proinflammatory and oxidative stressaccelerating PGs as well as HETE and HODE. Oxidative stress, vascular inflammation, and endothelial dysfunction in turn augment the cyst expansion and activate the RAAS. 8-isoP, 8-isoprostane; ADMA, asymmetric dimethylarginine; ADPKD, autosomal dominant polycystic kidney disease; AngII, angiotensin II; eNOS, endothelial nitric oxide synthase; HCy, homocysteine; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; LOX, lipoxygenase; NO, nitric oxide; RAAS, renin-angiotensin-aldosterone system; SAH, Sadenosyl homocysteine; SAM, S-adenosyl methionine; SDMA, symmetric dimethylarginine.
Measurement of Biomarkers
Endothelial Dysfunction Markers. Endothelial dysfunction markers, including arginine, asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), citrulline, cysteine, homocysteine (HCy), methionine (Met), S-adenosylhomocysteine (SAH), and S-adenosylmethionine (SAM), were quantified in plasma using an HPLC-tandem mass spectrometry (MS/MS) assay (27) . In brief, the API5000 mass spectrometer (AB Sciex, Concord, ON, Canada) was run in the positive electrospray ionization mode (ESI) using multiple reaction monitoring (MRM Urinary PGs. Urinary PGs were analyzed on an HPLC system interfaced with an API5000 tandem mass spectrometer operated in the negative ESI mode. The following ion transitions (MRM mode) were monitored for the study compounds: m/z 353.2→193.1 for 8-isoprostane, PGF 2a , and 9a,11b-PGF 2 ; m/z 351.2→189.2 for PGD 2 , D12-PGD 2 , and PGE 2 ; m/z 333.4→233.2 for PGJ 2 ; m/z 315.2→271.3 for 15d-PGJ 2 ; and 438.2→235.1 for leukotriene E4. The following deuterated internal standards were used: 8-isoprostaned4, PGF 2a -d9, 9a,11b-PGF 2 -d4, PGD 2 -d9, PGE 2 -d9, 15d-PGJ 2 -d4, and leukotriene E4-d5 (Cayman Chemical Company, Ann Arbor, MI).
Bioactive Lipid Mediators. Bioactive lipid mediators were analyzed in plasma and urine samples using a modification of a previously described HPLC-tandem mass spectrometry assay (16, 28) . The API5500 mass spectrometer was run in the positive ESI MRM mode. The following hydroxyfatty acids were quantified: 9-hydroxyoctadecadienoic acid (HODE), 13-HODE, 8-HETE, 9-HETE, 12-HETE, 15-HETE, 20-HETE, and 15-hydroxyeicosapentaenoic acid. All compounds, including the internal standards, 12-HETE-d8, 20-HETE-d6, 9-HODE-d4, and 13-HODE-d4, were purchased from Cayman Chemicals (Ann Arbor, MI, USA).
Urinary Metabolites. Citrate, succinate, hippurate, uric acid, glucose, creatinine, a-ketoglutarate, and lactate were quantified in urine samples. The internal standard solution contained d6-glucose, d3-creatinine, d5-hippurate, and d4-succinate. All samples were analyzed on a positive/negative electrospray API4000 mass spectrometer (AB Sciex).
For more detail on the mass spectrometry methods, please refer to the Supplemental Material.
Statistical Analyses
All of the biomarkers were natural logarithm for analysis because the distributions were skewed. ANOVA was used to compare the change (D) in markers. Linear regression was used to evaluate the relationship of each biomarker with HtTKV. Three models were run for each marker: (1) unadjusted, (2) adjusted for age and sex, and (3) adjusted for age, sex, systolic BP, and log-transformed GFR. Although the original study was powered for a combined end point of 20% increase in LVMI, TKV, or urinary microalbumin excretion, this study was primarily exploratory. SPSS (version 21.0; SPSS, Chicago, IL) and SAS (version 9.3; SAS Institute, Cary, NC) software was used for the statistical analyses. A P value ,0.05 was considered significant.
Results
Patient Characteristics
From 110 participants enrolled in the clinical trial, 101 plasma and 107 urine samples collected at baseline were available and were used for the biomarker analysis. The baseline characteristics are presented in Table 1 . We randomized 56 patients to the pravastatin group and 54 patients to the placebo group. Ninety-one participants completed the 3-year study, resulting in an overall completion rate of 83%. From these, 88 plasma samples and 85 urine samples were available for the biomarker analysis, again without any preselection process. Table 2 represents a summary of biomarker concentrations at baseline and after 3 years in either the placebo or pravastatin group compared with normal ranges reported in healthy individuals (adults and/or children, where available). Unfortunately, the majority of normal ranges for the investigated biomarkers have only been reported in healthy adult individuals. The mean age of our study participants was 1664 years; thus, some variance in the comparison of the measured values and the reported adult normal range can be expected. Children and young adults with ADPKD appeared to have lower plasma concentrations of Met compared with the healthy adults (at baseline; Table 2 ). Furthermore, plasma levels of proinflammatory and oxidative stress markers 9-HODE, 13-HODE, 12-HETE, and 15-HETE were elevated compared with those in healthy adults (at baseline); although they further increased in the placebo group, treatment with pravastatin led to their decline (Tables 2 and 3) .
Changes in Biomarker Concentrations over Time and Comparison with Healthy Individuals
In urine, citrate levels were in the same range as in healthy adults and declined in the placebo group, with no change in the pravastatin group (Table 2) . Similarly, PGF 2a declined more strongly in the patients receiving placebo compared with those taking pravastatin ( Table 2 ). This decline, however, appeared to be toward normal levels reported in healthy adults (Table 2) . By contrast, urinary 8-HETE, which was in the normal range at baseline, increased only in patients receiving pravastatin ( Table 2) .
Correlations of Plasma Biomarkers
When the percent change in HtTKV over 3 years was regressed against the log-transformed biomarker concentration, only the change in Met was positively associated with the change in HtTKV in the placebo group (unadjusted model, P=0.02). In the pravastatin group, 13-HODE was inversely associated with the change in HtTKV ( Table 4) .
Correlations of Urine Biomarkers
There were no significant differences in change in biomarker concentration between the pravastatin and placebo groups, using ANOVA. Regression analysis of the percent change in HtTKV over 3 years in all patients versus the log-transformed biomarkers (unadjusted, model 1 adjusted for age and sex, and model 2 adjusted for age, sex, log-transformed GFR, and systolic BP) revealed significant inverse associations with citrate (estimate 6 SEM, 20.00460.002 mmol/mmol creatinine; 95% confidence limits, 20.01 to 20.001; P=0.02 for model 2) and PGF 2a (estimate 6 SEM, 20.00360.001 mg/mmol creatinine; 95% confidence limits, 20.01 to 20.001; P=0.02 for model 2).
Citrate and PGF 2a urine concentrations were inversely associated with the change in HtTKV over 3 years in the placebo group, whereas 8-HETE, 9-HETE, and 11-HETE were positively associated with the change in HtTKV in the pravastatin group (Table 5) .
Discussion
ADPKD is the fourth most common cause of ESRD. The disease course and risk factors for ADPKD progression have not been well described in large cohorts of children. Because the structural disease starts early and renal function is maintained within the normal range for some decades (5, (29) (30) (31) , identifying risk markers early in the course might provide the basis for effective intervention and minimization of complications in patients with ADPKD.
Experimental evidence in rats has shown that statins decrease the severity of functional and structural disease in ADPKD (6, 7, 32) . In adult patients with ADPKD, 4-week administration of simvastatin improved renal blood flow and GFR (8) . Moreover, statins are beneficial for Table 3 . Difference in concentrations of plasma biomarkers between study groups (pravastatin versus placebo) over the 3-year study period compared with the baseline
Variable (D)
P r a v a s t a t i n P l a c e b o P Value endothelial dysfunction (33) (34) (35) , which is known to occur early in patients with ADPKD, even before the onset of hypertension (36) . Therefore, we designed a 3-year randomized study to examine the effects of statin treatment on kidney volume growth, LVMI, and urinary microalbumin excretion in children and young adults with ADPKD (9). The results showed that the percent increase in HtTKV adjusted for age, sex, and hypertension status over the 3-year period was significantly decreased with pravastatin (10) .
Plasma concentrations of 9-HODE and 13-HODE, which are both metabolites of linoleic acid through oxidation by 15-lipoxygenase (LOX) and cyclooxygenases (COXs) into 13-HODE (37) (38) (39) and by COX into 9-HODE (37), and 12-HETE and 15-HETE (12-LOX/15-LOX metabolites of AA) were elevated in children and young adults with ADPKD compared with the levels reported in healthy adults. This confirms our findings as well as results of other studies, showing that adult patients with ADPKD have higher levels of these bioactive lipids compared with healthy individuals and that their concentrations are associated with increased TKV and/or decreased renal function (14, 16) . These COX and LOX metabolites have been shown to directly function as key mediators of angiotensin II-induced renin inhibition (40, 41) . They have also been shown to activate the peroxisome proliferator-activated receptor g, known to be implicated in cyst growth (42) .
Furthermore, our results showed that changes in plasma levels of proinflammatory and oxidative stress markers 9-HODE, 13-HODE, and 15-HETE over 3 years were significantly different between the placebo and pravastatin groups, with the pravastatin group showing a decline and, thus, improvement, compared with the placebo group. Because the renin-angiotensin-aldosterone system is suspected to be a major contributor to cyst growth in both animals and humans with ADPKD (43, 44) , the ability of pravastatin to reduce the plasma concentrations of these COX and LOX metabolites over 3 years could represent a potential molecular mechanism by which pravastatin reduces cyst growth. This hypothesis is further supported by a separate mechanistic study, in which lovastatin was successful in reducing the 13-HODE and 12-HETE plasma levels that were significantly elevated in cystic Cy/+ Han: Sprague-Dawley rats (7) .
Changes in urinary citrate and PGF 2a were negatively associated with the percent change in HtTKV over 3 years in the placebo group. Pravastatin treatment seemed to counteract the citrate decline that was also previously shown to occur in patients with ADPKD during disease progression (45) . In regard to PGF 2a , both patient groups showed lower urinary levels at 3 years than at the baseline.
Furthermore, we identified urinary 8-HETE, 9-HETE, and 11-HETE to be positively associated with the change in HtTKV in the pravastatin group. This is an interesting finding because the mean levels of plasma 8-HETE and 11-HETE were lower in the pravastatin group than in the placebo group after 3 years (corrected for baseline). A possible explanation is that pravastatin therapy leads to an enhanced clearance and elimination of these mediators, causing a reduction in their concentrations in blood and potentially in kidney tissue. Supporting this conclusion was an observation made in cystic rats, in which lovastatin treatment decreased (albeit not significantly) kidney tissue concentrations of 8-HETE, 9-HETE, and 12-HETE, which were significantly higher in the kidneys of cystic rats (7) .
The mechanisms underlying the effect of pravastatin on structural kidney disease in pediatric ADPKD require further elucidation. Our results suggest that statins might have an effect on the metabolism of polyunsaturated fatty acids, via regulation of COX and LOX activities, resulting in reduced production of proinflammatory and endothelial dysfunction-inducing bioactive lipids. This in turn might alter cell proliferation and signal transduction pathways (46) (47) (48) , changing the formation and expansion of kidney cysts in ADPKD. The next step is to investigate whether the adult ADPKD population could also benefit from statins early in the course of their disease, especially before a detectable decline in GFR. It should be noted that this study uses a unique cohort of children with well defined ADPKD, with normal creatinine clearance and low frequency of left ventricular hypertrophy, who participated in a study of pravastatin effect on disease progression (9, 10) . Long-term stability data exceeding 12 months were not available for any of the measured biomarkers; however, the majority of the biomarkers were stable at 270°C or below for 12 months. In addition, regression analysis without adjustments for multiple comparisons leaves a risk of type I and type II statistical errors.
In conclusion, our findings provide a rationale for further evaluation of the potential clinical value of these markers as predictive and monitoring diagnostic tools in longitudinal prospective clinical studies of patients with ADPKD. Furthermore, the clinical outcome strongly suggests that early intervention in ADPKD may be warranted.
